Literature DB >> 30655902

miR-106a contributes to prostate carcinoma progression through PTEN.

Ji Lu1, Xupeng Mu2, Qinan Yin3,4, Kebang Hu1.   

Abstract

Prostate carcinoma is a global health problem and is estimated to be diagnosed in 1.1 million men/year, making this malignancy the second most frequently diagnosed cancer in males worldwide. micro RNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at the post-transcriptional level. miRNAs contribute to cancer development and progression, and are expressed differently in normal tissues and cancers. In the present study, the biological function of miR-106a in the human prostate carcinoma and the associated regulatory mechanisms were investigated. miR-106a was significantly upregulated in human prostate cancer tissues when compared with normal tissues (P<0.05), and the overexpression of miR-106a was identified to promote PC-3 cell growth. Additionally, miRNA-106a inhibition significantly suppressed PC-3 cell growth. Furthermore, it was observed that the phosphatase and tensin homolog (PTEN) expression level was negatively associated with miR-106a expression level, and miRNA-106a directly targeted PTEN in the PC-3 cells. PTEN overexpression has a similar effect on PC-3 cell growth as loss of miR-106a. Taken together, the results of the present study indicate that upregulated miR-106a regulates PC-3 cell proliferation through PTEN. These results suggest that appropriate manipulation of miR-106a may provide a novel strategy in the future treatment of human prostate cancer.

Entities:  

Keywords:  cell proliferation; miR-106a; phosphatase and tensin homolog; prostate carcinoma

Year:  2018        PMID: 30655902      PMCID: PMC6313013          DOI: 10.3892/ol.2018.9697

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  5 in total

1.  Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.

Authors:  Roberto H Barbier; Edel M McCrea; Kristi Y Lee; Jonathan D Strope; Emily N Risdon; Douglas K Price; Cindy H Chau; William D Figg
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.996

Review 2.  The Complex Landscape of PTEN mRNA Regulation.

Authors:  Erin Sellars; Martino Gabra; Leonardo Salmena
Journal:  Cold Spring Harb Perspect Med       Date:  2020-06-01       Impact factor: 5.159

3.  LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma.

Authors:  Nuobei Zhang; Hao Shen; Shenan Huang; Fenfen Wang; Huifang Liu; Fen Xie; Lei Jiang; Xin Chen
Journal:  Eur J Histochem       Date:  2021-11-16       Impact factor: 3.188

Review 4.  The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.

Authors:  Daniel J Turnham; Nicholas Bullock; Manisha S Dass; John N Staffurth; Helen B Pearson
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

5.  Emerging Role of Extracellular Vesicles in Prostate Cancer.

Authors:  Megan Ludwig; Rhea Rajvansh; Justin M Drake
Journal:  Endocrinology       Date:  2021-09-01       Impact factor: 4.736

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.